Abstract:Non-alcoholic fatty liver disease (NAFLD) is a major health care problem and represents the hepatic expression of the metabolic syndrome. NAFLD is classified as non-alcoholic fatty liver (NAFL) or simple steatosis, and non-alcoholic steatohepatitis (NASH). NASH is characterized by the presence of steatosis and inflammation with or without fibrosis. The physiopathology of NAFL and NASH and their progression to cirrhosis involve several parallel and interrelated mechanisms, such as, insulin resistance (IR), lipotoxicity, inflammation, oxidative stress, and recently the gut-liver axis interaction has been described. Incretin-based therapies could play a role in the treatment of NAFLD. Glucagon-like peptide-1 (GLP-1) is an intestinal mucosa-derived hormone which is secreted into the bloodstream in response to nutrient ingestion; it favors glucose-stimulated insulin secretion, inhibition of postprandial glucagon secretion and delayed gastric emptying. It also promotes weight loss and is involved in lipid metabolism. Once secreted, GLP-1 is quickly degraded by dipeptidyl peptidase-4 (DPP-4). Therefore, DPP-4 inhibitors are able to extend the activity of GLP-1. Currently, GLP-1 agonists and DPP-4 inhibitors represent attractive options for the treatment of NAFLD and NASH. The modulation of lipid and glucose metabolism through nuclear receptors, such as the farsenoid X receptor, also constitutes an attractive therapeutic target. Obeticholic acid is a potent activator of the farnesoid X nuclear receptor and reduces liver fat content and fibrosis in animal models. Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with immunomodulatory, anti-inflammatory, antiapoptotic, antioxidant and anti-fibrotic properties. UDCA can improve IR and modulate lipid metabolism through its interaction with nuclear receptors such as, TGR5, farnesoid X receptor-α, or the small heterodimeric partner. Finally, pharmacologic modulation of the gut microbiota could have a role in the therapy of NAFLD and NASH. Probiotics prevent bacterial translocation and epithelial invasion, inhibit mucosal adherence by bacteria, and stimulate host immunity. In animal models, probiotics prevent obesity, decrease transaminase levels, and improve IR and liver histology in NASH.

Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg

Gasotransmitter Research Advances in Respiratory Diseases.

Gasotransmitters and the mechanisms for cardiovascular diseases

Research Progress on the Mechanism of Traditional Chinese Medicine in the Treatment of Non-Alcoholic Fatty Liver Disease Based on Oxidative Stress

Gasotransmitters: Growing Pains and Joys

Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders

From Nitric Oxide to Hyperbaric Oxygen: Invisible and Subtle but Nonnegligible Gaseous Signaling Molecules in Acute Pancreatitis.

Microbial Metabolites: Critical Regulators in NAFLD

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

From Nitric Oxide to Hyperbaric Oxygen

Role of Gasotransmitters in the Pathogenesis of Pulmonary Hypertension

The Gut Microbiota and its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.

A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease

Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets

The Molecular and Mechanistic Insights Based on Gut–Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease

Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD)

Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets

Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)